Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Miyarisan Pharmaceutical Co. Ltd. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units. LANKFORD JR, LEON B is the busiest examiner, holding 1 pending office action.
With 2 pending office actions and 2 distinct examiners, the company faces a fragmented prosecution landscape where each case is subject to a different individual's scrutiny. The involvement of 2 distinct art units further suggests that the technologies being patented are distinct enough to fall under different examination specialties. Practitioners should note that LANKFORD JR, LEON B only oversees 1 pending office action, meaning there is no centralized examiner to negotiate with for the bulk of the docket. This requires the legal team to monitor two separate sets of deadlines and examiner-specific behaviors. The presence of 2 distinct examiners for the 2 pending office actions highlights the need for individualized attention to each application's unique requirements. This decentralized structure for a small portfolio requires careful attention to ensure that arguments made to one examiner do not conflict with those made to the other.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LANKFORD JR, LEON B | 1 | 70.0% | +31.5% |
| KOROTCHKINA, LIOUBOV G | 1 | 29.0% | +64.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18548703 | INTERFERON PRODUCTION PROMOTER | KOROTCHKINA, LIOUBOV G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18728704 | FORMULATION COMPOSITION | LANKFORD JR, LEON B | — |
| 18548703 | INTERFERON PRODUCTION PROMOTER | KOROTCHKINA, LIOUBOV G | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18728704 | FORMULATION COMPOSITION | LANKFORD JR, LEON B | 1657 | §103 | Non-Final OA | — | Pending | Jul 12, 2024 |
| 18548703 | INTERFERON PRODUCTION PROMOTER | KOROTCHKINA, LIOUBOV G | 1653 | §103 | Non-Final OA | — | Pending | Sep 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMiyarisan Pharmaceutical Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Leon B Lankford Jr. has the most, with 1 of Miyarisan Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
